若生智能
Drug Database
BE

bevacizumab (Abevmy / bevacizumab, Biocon / Krabeva)

✓ Approved

Mylan · VEGFA · 单克隆抗体

什么是 bevacizumab？

bevacizumab 是一种单克隆抗体，由Mylan研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Intravenous (IV)。

药物档案

商品名Abevmy, bevacizumab, Biocon, Krabeva
公司Mylan
药物类别单克隆抗体, 抗体
分子靶点VEGFA
给药途径Injectable (Others), Intravenous (IV)
状态Approved
来源： ClinicalTrials.gov, Mylan

作用机制

分子靶点

bevacizumab 作用于 1 个分子靶点：

VEGFAvascular endothelial growth factor A (VPF, MVCD1)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

bevacizumab 针对 9 个适应症，涉及 2 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer stage IV✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Non-small cell lung cancer metastatic✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Brain neoplasm malignant✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Breast cancer✓ Approved
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Fallopian tube cancer✓ Approved

注册免费账户还可查看另外 4 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedHuman vaccines & immunotherapeutics2026-07-27

Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China.

Xu Huihui H, Yu Shengjian S, Yang Yan Y, Bian Haoze H et al.

Hepatocellular carcinoma (HCC) imposes a substantial health burden in China. Finotonlimab plus bevacizumab recently prolonged progression-free survival (PFS) and overall survival (OS) vs. sorafenib, but its economic value remains unknown. Here we evaluated the cost-effectiveness of finotonlimab plus bevacizumab vs. sorafenib from the Chinese healthcare system perspective. Parametric survival models were fitted to extrapolate PFS and OS. Total costs, life-years (LYs), quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), incremental net monetary benefit (INMB), and incremental net health benefit (INHB) were estimated at a willingness-to-pay (WTP) threshold of $27,906 per QALY. Uncertainty was evaluated by one-way and two-way sensitivity analyses, probabilistic sensitivity analysis (PSA), subgroup analyses, scenario analyses, and price simulations. In the base-case analysis, sorafenib yielded 1.74 LYs and 1.25 QALYs at a total cost of $10,303.10, whereas finotonlimab plus bevacizumab yielded 3.01 LYs and 2.18 QALYs at a total cost of $58,595.49. Compared with sorafenib, the combination increased costs by $48,292.39 and generated gains of 1.27 LYs and 0.93 QALYs, resulting in ICERs of $38,203.46 per LY and $51,899.31 per QALY. INMB (-$22,325.82) and INHB (-0.80 QALYs) were negative. Sensitivity analyses identified PFS utility and bevacizumab cost as key drivers, but all ICERs remained above the WTP threshold. In PSA, the mean ICER was $50561.81 per QALY, and the probability of cost-effectiveness was 0% at the prespecified threshold. Based on the assumptions and inputs used in the present model, finotonlimab plus bevacizumab was unlikely to be cost-effective compared with sorafenib at the prespecified WTP in China.

PMID 42505057
阅读全文 →
PubMedNeurology international2026-07-27

Headache as a Sentinel Signal After Cranial Radiotherapy: A Symptom-Driven Approach to Pathophysiology and Management.

Lunguț Silviu S, Turcu Suzana S, Glavce Cristiana C

Headache is a frequent and clinically relevant symptom in patients undergoing cranial radiotherapy, most often reflecting treatment-induced structural and inflammatory changes such as cerebral edema or radiation-related brain injury. Differentiating secondary headache from primary disorders, particularly migraine, is essential for appropriate management. This review aims to examine the pathophysiological mechanisms underlying headache following cranial radiotherapy, evaluate current pharmacological and complementary treatment strategies and highlight key aspects of differential diagnosis with migraine. Unlike existing literature that focuses primarily on radiological findings of radiation injury, this review adopts a symptom-driven approach, reframing headache as a critical clinical gateway for the early detection of structural complications. A structured narrative review of the literature was conducted using PubMed/MEDLINE, Scopus and Google Scholar to identify studies published between 2020 and 2025, focusing on cerebral edema, radiation-related complications, therapeutic approaches and migraine. Relevant clinical trials, systematic reviews and guidelines were included. Cerebral edema consistently emerges as the main mechanism of acute and subacute post-radiotherapy headache, whereas late-onset symptoms are most often linked to radiation necrosis. Corticosteroids remain first-line therapy, while bevacizumab has demonstrated benefit in steroid-refractory cerebral edema and radiation necrosis through inhibition of vascular endothelial growth factor (VEGF), thereby reducing vascular permeability and attenuating peritumoral edema. Its use in the context of cranial radiotherapy requires careful consideration, as the safety of concomitant administration with radiation has not been formally established, and headache itself is among its recognized adverse effects. Evidence for complementary therapies, including Boswellia serrata and plant-based compounds, remains limited. Migraine constitutes a distinct neurovascular disorder requiring careful differentiation from secondary headache in oncological patients. The review emphasizes headache as a clinically relevant indicator of underlying structural complications rather than an isolated symptom. Post-radiotherapy headache should be interpreted as a manifestation of underlying structural pathology. Accurate etiological diagnosis and individualized management are essential. Further research is needed to refine treatment strategies and clarify the role of complementary therapies.

PMID 42506054
阅读全文 →
PubMedTherapeutic advances in medical oncology2026-07-26

Bevacizumab plus iparomlimab/tuvonralimab with hepatic artery infusion chemotherapy followed by stereotactic body radiotherapy in patients with BCLC stage C hepatocellular carcinoma with thrombus and/or extrahepatic oligometastases (BITS-TO-HCC): study protocol of a prospective, single-center, single-arm, phase II study.

Liu Yuxin Y, Wang Haohua H, Zhu Kunli K, Jiang Shumei S et al.

First-line immunotherapy-based combinations have improved outcomes in advanced hepatocellular carcinoma (HCC), but many patients with Barcelona Clinic Liver Cancer (BCLC) stage C HCC with portal vein tumor thrombus (PVTT) and/or extrahepatic oligometastases remain difficult to treat and often unresectable. To characterize the safety, feasibility, and efficacy of a sequential strategy combining hepatic artery infusion chemotherapy with infusional fluorouracil, leucovorin, and oxaliplatin (HAIC-FO), iparomlimab/tuvonralimab plus bevacizumab, followed by stereotactic body radiotherapy (SBRT), in patients with BCLC stage C HCC with PVTT and/or extrahepatic oligometastases. The BITS-TO-HCC study is a prospective, single-center, single-arm, phase II trial. Patients with BCLC stage C HCC complicated by PVTT and/or extrahepatic oligometastases and Child-Pugh class A liver function will be enrolled. On day 1 of each cycle, patients will receive HAIC-FO followed by bevacizumab plus iparomlimab/tuvonralimab after protocol-defined laboratory reassessment. HAIC-FO will be delivered for up to four cycles. After cycle 4, patients without progressive disease will receive protocol-specified SBRT (25-40 Gy in 5 fractions). Patients with radiographic complete response or no residual SBRT-amenable lesion will continue systemic therapy and follow-up. The primary endpoint is progression-free survival. Secondary endpoints include objective response rate, disease control rate, overall survival, local control rate, safety, and quality of life. The final protocol was approved by the Ethics Committee of the Affiliated Cancer Hospital of Shandong First Medical University. This trial will prospectively evaluate whether a sequential strategy combining HAIC with bevacizumab plus iparomlimab/tuvonralimab followed by SBRT can provide a surgery-sparing, ablative locoregional-systemic pathway for this high-risk population, potentially enhancing efficacy while maintaining an acceptable safety profile. Trial registration: This study is registered on ClinicalTrials.gov Identifier: NCT07062055 (July 14, 2025).

PMID 42502358
阅读全文 →
PubMedMolecular carcinogenesis2026-07-26

Myeloid Focal Adhesion Kinase Promotes Macrophage Accumulation but Does Not Alter Tumor Progression in Hepatocellular Carcinoma.

Ham Eugene E, Boedeker Kyle K, Keating Claudia Rose CR, Ye Ruisong R et al.

Hepatocellular carcinoma (HCC) develops within an immunologically complex tumor microenvironment that is heavily shaped by infiltrating myeloid cells. Immune-based treatment strategies such as atezolizumab plus bevacizumab have shown promising therapeutic benefits, but patients do not experience durable responses. This shortfall motivates current efforts to elucidate signaling programs that sustain pro-tumor myeloid states. Focal adhesion kinase (FAK, encoded by PTK2) integrates adhesion, growth factor, proliferative, and inflammatory signaling, but the contribution of FAK in myeloid cells to HCC has not been tested. In this study, we used human HCC transcriptomic analyses and a myeloid-specific FAK knockout mouse model to investigate the role of myeloid-intrinsic FAK in HCC progression. Analysis of the PRHCCdb single-cell database showed PTK2 expression was detectable in myeloid populations. Higher PTK2 expression in myeloid-rich TCGA-LIHC tumors was associated with a significantly worse overall survival. Further analysis of the NCI-CLARITY single-cell data set localized the strongest FAK-associated transcriptional programs to a monocyte-derived macrophage state marked by VCAN and COLEC12. Specifically, this population demonstrated hypoxia-associated and inflammatory signatures. To test the functional role of FAK in myeloid cells, we generated myeloid-specific FAK knockout (LysMCre;FAKf/f) mice. Deletion of FAK did not alter baseline liver morphology, liver-to-body weight ratio, or proliferation. When challenged with the MET/β-catenin-driven HCC model via hydrodynamic tail vein injection, myeloid-specific FAK deletion did not significantly affect survival, gross tumor burden, or tumor proliferation. However, tumors from the LysMCre;FAKf/f mice showed significantly reduced F4/80+ macrophage accumulation compared with FAKf/f controls. These findings indicate that myeloid-specific FAK promotes macrophage accumulation, but its loss alone is insufficient to alter tumor burden, proliferation, or survival in this oncogene-driven HCC model.

PMID 42503231
阅读全文 →
PubMedTargeted oncology2026-07-26

Changing Treatment Landscape of Hepatocellular Carcinoma: A Real-World Retrospective Analysis of Treatment Algorithms and Outcomes of Patients over 10 Years.

Bathon Melanie M, Binder Nele N, Welland Sabrina S, Gerdes Christoph C et al.

Hepatocellular carcinoma is one of the most common cancers worldwide and the third leading cause of cancer-related mortality. The therapeutic landscape of hepatocellular carcinoma, especially systemic therapies, is constantly changing and characterized by a multimodal approach. The aim of this study was to investigate whether and how treatment sequencing according to tumor stage and liver function has changed over time and if the introduction of new therapeutic options has led to improved survival rates. Therapy concepts were retrospectively recorded and evaluated in a cohort of 1288 patients with hepatocellular carcinoma with a first diagnosis between January 2013 and December 2022 who were divided into two cohorts with a cut-off for dividing in 2020 owing to the approval of atezolizumab and bevacizumab for the treatment of hepatocellular carcinoma by the European Medicines Agency (Cohort A initial diagnosis 2013-19, Cohort B initial diagnosis 2020-22). All patients were treated at Hannover Medical School, Germany. Baseline characteristics differed significantly between cohorts, with Cohort B presenting at earlier tumor stages and with better preserved liver function. Across all treatment modalities, liver function emerged as the primary determinant of prognosis, independent of tumor stage and performance status. Over time, a treatment shift from transarterial chemoembolization towards systemic therapies was observed. Median overall survival from initial diagnosis did not differ between cohorts. In unadjusted analyses, patients treated with immune checkpoint inhibitor-based regimens demonstrated longer median overall survival compared with those receiving tyrosine kinase inhibitors. However, after multivariable adjustment for baseline imbalances, no independent survival difference between treatment groups remained. This study provides a detailed longitudinal assessment of evolving treatment patterns and outcomes, highlighting a clear shift in therapeutic strategies over time with the increasing adoption of systemic therapies. Despite evolving treatment strategies and increased use of systemic therapies, liver function remained the dominant prognostic factor across treatment settings. Observed survival differences between treatment modalities were strongly influenced by baseline patient characteristics and treatment selection.

PMID 42503051
阅读全文 →
PubMedMedicine2026-07-25

Efficacy and prognostic factors of first-line bevacizumab plus chemotherapy in elderly patients with advanced driver gene-negative lung adenocarcinoma: A retrospective study.

Li Shuiyao S, Wang Shaojun S, Cao Ranhua R

We aimed to evaluate clinical outcomes and identify prognostic indicators in elderly patients with driver gene-negative advanced lung adenocarcinoma treated with first-line bevacizumab-based therapy. Elderly patients (≥65 years) with driver gene-negative advanced lung adenocarcinoma treated between January 2020 and December 2024 were retrospectively included. According to first-line treatment strategies, patients were divided into a chemotherapy-alone group and a bevacizumab plus chemotherapy group. Progression-free survival (PFS) and overall survival (OS) were analyzed using univariate and multivariate Cox regression models. A total of 169 patients were included. In the bevacizumab group, the median OS was 47 months and the median PFS was 24 months. Multivariate analysis showed that prognostic nutritional index (PNI), vascular endothelial growth factor A, carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA-125), and bevacizumab treatment were independent prognostic factors for PFS. Additionally, neutrophil-to-white blood cell ratio (NWR), neutrophil-to-lymphocyte ratio, PNI, vascular endothelial growth factor A, CA-125, and bevacizumab treatment were independently associated with OS. Our findings suggest that bevacizumab combined with chemotherapy is associated with favorable survival outcomes in elderly patients with driver gene-negative advanced lung adenocarcinoma. Inflammation-, nutrition-, and tumor burden-related biomarkers may help predict survival and assist in risk stratification.

PMID 42499069
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多bevacizumab